激活素II型受体信号在HFpEF合并肺动脉高压中的作用:生物学机制与临床试验的批判性分析
本文批判性分析HFpEF合并混合性毛细血管前后肺动脉高压(CpcPH-HFpEF)中激活素II型受体信号的作用。证据提示心外膜脂肪释放的激活素A通过激活素II型受体信号促进肺静脉和左心房纤维化与重构。CADENCE试验显示sotatercept降低肺动脉楔压和左心房容积指数,III期结局试验正在进行。
要点
- CpcPH-HFpEF的肺血管阻力升高机制与肺动脉高压不同,肺静脉和左心房功能障碍可能起核心作用。
- 心外膜脂肪释放的激活素A通过激活素II型受体信号促进肺静脉和左心房重构与纤维化。
- CADENCE试验显示sotatercept降低CpcPH-HFpEF患者肺动脉楔压和左心房容积指数。
核心结论
- 证据总体表明CpcPH-HFpEF的肺血管阻力升高机制与肺动脉高压不同,激活素A/激活素II型受体信号是HFpEF发病中的关键脂肪因子介质。
研究设计与样本
- 本文为对生物学机制与临床试验的批判性分析,未报告原始研究样本量。
主要发现
- 心外膜脂肪扩张释放的激活素A通过激活素II型受体信号导致 underlying 组织纤维化、心肌细胞僵硬和衰老。
- 循环激活素A在左心房扩大、肺静脉高压和肺血管阻力增高的HFpEF患者中升高。
- 实验模型中激活素A信号促进心房肌病和HFpEF发生,激活素II型受体配体陷阱可减轻肥胖诱导的CpcPH-HFpEF模型中的肺血管和左心异常。
- CADENCE试验显示sotatercept降低CpcPH-HFpEF患者肺动脉楔压和左心房容积指数,该效应不能由肺血管阻力下降解释。
临床怎么用
- 激活素A/激活素II型受体信号可作为CpcPH-HFpEF的潜在治疗靶点,sotatercept的疗效正在III期结局试验中验证。
局限性
- 本文为批判性分析,未报告原始研究的具体样本量、效应量和统计显著性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The totality of evidence indicates that the mechanisms underlying the increase in pulmonary vascular resistance in patients with combined postcapillary and precapillary pulmonary hypertension (CpcPH) associated with heart failure with preserved ejection fraction (HFpEF) differ meaningfully from those responsible for the increase in pulmonary vascular resistance in patients with pulmonary arterial hypertension. CpcPH-HFpEF is a complex disorder involving the pulmonary veins, left atrium, and pulmonary arterioles, but recent evidence has highlighted a potentially central role for pulmonary venous and left atrial (LA) dysfunction. Epicardial adipose tissue occupies anatomical proximity to both structures, allowing derivative secretory products to influence their structure and function. The most well-characterized proinflammatory adipokine released from an expanded epicardial fat mass is activin A, which causes fibrosis and cardiomyocyte stiffness and senescence in underlying tissues by signaling through activin type II receptor signal transduction. Such signaling regulates pulmonary venular responses to mechanical stretch, and circulating activin A is elevated in patients with HFpEF who have enlarged LA chambers, pulmonary venous hypertension and increased pulmonary vascular resistance. The adipokine hypothesis of HFpEF identified activin A and activin type II receptor signaling as key adipokine mediators in the pathogenesis of HFpEF. Experimentally, activin A signaling promotes the development of both atrial myopathy and HFpEF, and activin type II receptor ligand traps alleviate HFpEF and ameliorate both the pulmonary vascular and left heart abnormalities in experimental models in which CpcPH-HFpEF is induced by obesity. These collective observations led to the prospective hypothesis that adipokine modulation by sotatercept would mediate benefits on the left heart in patients with CpcPH-HFpEF. These expectations were validated when the CADENCE trial showed that sotatercept decreased both pulmonary artery wedge pressures and left atrial volume index in patients with CpcPH-HFpEF, which are effects that could not explained by a decrease in pulmonary vascular resistance. Activin A released from an expanded epicardial adipose tissue promotes both pulmonary venous and left atrial remodeling and fibrosis in vivo, which (in turn) are effects that can be attenuated by an activin A decoy. The efficacy of sotatercept to slow the progression of CpcPH-HFpEF is now being tested in a phase III outcomes trial.
引用
- Packer M, Gomberg-Maitland M, Tedford RJ, et al. Effect of Activin Type II Receptor Signaling in Patients With HFpEF and Pulmonary Hypertension: A Critical Analysis of Biological Mechanisms and Clinical Trials. Circulation. 2026. PMID: 42932419. doi:10.1161/CIRCULATIONAHA.126.081957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。